Nuveen LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRE

Nuveen LLC acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 140,129 shares of the company’s stock, valued at approximately $2,261,000. Nuveen LLC owned 0.23% of Spyre Therapeutics as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of Spyre Therapeutics by 38.8% in the fourth quarter. Wells Fargo & Company MN now owns 24,718 shares of the company’s stock valued at $575,000 after buying an additional 6,908 shares during the period. First Trust Advisors LP acquired a new position in Spyre Therapeutics in the 4th quarter worth $548,000. MetLife Investment Management LLC increased its holdings in Spyre Therapeutics by 6.2% during the 4th quarter. MetLife Investment Management LLC now owns 21,382 shares of the company’s stock worth $498,000 after purchasing an additional 1,250 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Spyre Therapeutics by 1,548.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company’s stock worth $200,000 after purchasing an additional 8,054 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Spyre Therapeutics by 18.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 506,450 shares of the company’s stock valued at $11,791,000 after purchasing an additional 77,323 shares during the period. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Trading Down 1.4%

Shares of SYRE opened at $16.49 on Friday. The company’s fifty day simple moving average is $16.29 and its 200 day simple moving average is $16.36. Spyre Therapeutics, Inc. has a 1-year low of $10.91 and a 1-year high of $40.26. The company has a market cap of $996.00 million, a price-to-earnings ratio of -4.85 and a beta of 2.82.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.24. As a group, research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

SYRE has been the subject of several recent research reports. Wall Street Zen raised Spyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 23rd. Wedbush reaffirmed an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $53.40.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).